GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » COGS-to-Revenue

Adicon Holdings (HKSE:09860) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings COGS-to-Revenue?

Adicon Holdings's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$0 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$0 Mil.

Adicon Holdings's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Adicon Holdings's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

Adicon Holdings COGS-to-Revenue Historical Data

The historical data trend for Adicon Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicon Holdings COGS-to-Revenue Chart

Adicon Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.59 0.57 0.61 0.57

Adicon Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial - 0.60 0.62 0.56 -

Adicon Holdings COGS-to-Revenue Calculation

Adicon Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2038.499 / 3607.095
=0.57

Adicon Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicon Holdings  (HKSE:09860) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Adicon Holdings's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Adicon Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicon Holdings (HKSE:09860) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:02325 HKSE:06667 HKSE:09960 HKSE:08037 HKSE:02427 HKSE:08225 HKSE:08247 HKSE:00928 TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
ADCNF:USA
Address
No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN
Website
https://www.adicon.com.cn
Adicon Holdings Ltd is one of the top three independent clinical laboratory or ICL, service providers in China. The company offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China. The high quality of its services is backed by its strong performance in terms of international accreditation and comprehensive testing menu. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests. It has three major service platforms. Among them, the inspection service platform consists of clinical, pathology, reproductive genetic, genetic, and mass spectrometry laboratories.
Executives
Cap V General Partner, L.p. 2201 Interest of corporation controlled by you
Cap V, L.l.c. 2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c. 2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c. 2201 Interest of corporation controlled by you
Pearl Group Limited 2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p. 2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p. 2201 Interest of corporation controlled by you
The Carlyle Group Inc. 2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited 2301 Trustee
Ingenuity Capital Holdings Limited 2201 Interest of corporation controlled by you
Corelink Group Limited

Adicon Holdings (HKSE:09860) Headlines

No Headlines